### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

#### **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	The 'Method'section, paragraph 2	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID	No cell materia were used	
<b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.	No primary cultures were performed	
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No laboratory animals were involved.	
Animal observed in or captured from the field: Provide species, sex and age where possible	No animals were observed in or captured from the field	
Model organisms: Provide Accession number in repository (where relevant) <b>OR</b> RRID	No model organisms were used	
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location	No plants were used	
<b>Microbes:</b> provide species and strain, unique accession number if available, and source	No microbes were used	

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	The 'Method'section, paragraph 1	
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	The informed consent was waived due to the	
obtained from study participants.	anonymous data and non-intervention feature of	
	the study.	

#### DRAFT | June 2019

Report on age and sex for all study participants.	The endpoints were not relevant to sex and age of the participants	
---	--	--

## Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.	This study is not a clinical trial.	
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	No detailed step-by-step protocol has been pre- defined	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, <b>or</b> if they were not carried out.		
Sample size determination	Sample size was not calculated based on analytical method.	
Randomisation	No randomisation was performed	
Blinding	No blinding was performed	
Inclusion/exclusion criteria	No inclusion/exclusion criteria was pre-defined	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	The experiment was not replicated in laboratory	
Define whether data describe technical or biological replicates	There were not technical or biological replicates	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The 'Method' section, paragraph 1	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No experimental animals were involved	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	No specimen and field samples were involved	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	This study is not dual use research	

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were	No sample or data point from the analysis was excluded	
determined and specified in advance.		
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	The 'Method'section, paragraph 6	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	No dataset was newly created	
If data are publicly available, provide accession number in repository or DOI or URL.	The data are not publicly available.	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	No publicly available data were reused	
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	No code or software was newly generated	
If code is publicly available, provide accession number in repository, or DOI or URL.	No code or software was newly generated	

## **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-21-3334